Hokusai VTE-Cancer Study: Edoxaban vs Dalteparin for VTE in Adult Cancer Patients

Slideset - Oral edoxaban was noninferior to subcutaneous dalteparin regarding combined risk of recurrent VTE or major bleeding in patients with cancer-associated VTE.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research